A cholesterol test you've never heard of is now recommended to prevent heart disease

The AHA and ACC released updated cholesterol guidelines recommending a one-time lipoprotein(a) test for all adults and broader use of coronary artery calcium scoring and the PREVENT risk tool to guide earlier lipid-lowering therapy. Roughly 25% of U.S. adults have high LDL; the guidance could increase testing and earlier statin initiation (statins are largely generic — anecdotal cost ~$3/month), boosting demand for diagnostic Lp(a) assays and calcium-scoring services. The shift toward lifetime-risk assessment is intended to reduce heart attacks and strokes through earlier, more intensive prevention.

Analysis

The guideline pivot to one-time Lp(a) screening and broader calcium scoring is a demand shock for diagnostics and outpatient imaging pathways rather than for generics. Expect a front-loaded bump in lab volumes and CT-calcium procedures concentrated in primary-care anchors and hospital outpatient centers over the next 6–18 months as systems operationalize order sets and EMR prompts; this creates a predictable revenue stream for centralized labs and imaging chains with minimal additional clinical complexity.

Mid-term (12–36 months) the more consequential effect will be patient stratification: identification of higher inherited risk cohorts will accelerate use of second-line lipid-lowering therapies (PCSK9 inhibitors, inclisiran-style siRNA, and Lp(a)-targeted drugs in trials). Because statins are cheap and sticky, drug uptake will be payer-driven and concentrated in high-risk, high-Lp(a) subpopulations — good for margin-rich specialty drugs but limited in absolute patient numbers until guideline-driven coverage changes occur.

Key downside vectors: payers may narrow coverage or require step therapy given cost differential versus statins, blunting pharma upside; reimbursement pressure on labs and imaging centers could compress per-test economics even as volumes rise. Operationally, winners are those who can scale testing with low marginal cost and convert downstream specialty referrals; losers are fragmented imaging sites and retail clinics that cannot invest quickly in CT access or EMR integration.

Key Decisions for Investors

• Long DGX (Quest Diagnostics) — 6–12 months. Rationale: immediate uplift in one-time Lp(a) testing and recurring lipid panels; position via 6–12 month calls or outright shares sized modestly. Risk/reward: modest upside (15–30%) against reimbursement/commercial execution risk; stop-loss ~12%.
• Long RDNT (RadNet) — 6–12 months. Rationale: outpatient imaging chains are best-placed to capture higher calcium-scoring volumes; buy shares or LEAP calls for capture of incremental CT utilization. Risk/reward: 2:1 upside if referral flows materialize vs downside if capital constraints slow capacity expansion.
• Directional long NVS (Novartis) — 12–36 months via call spread. Rationale: increased identification of patients who fail/are intolerant of statins improves addressable market for inclisiran/other novel LDL-lowering drugs; use a defined-risk call spread to capture upside from higher uptake while limiting premium loss. Risk/reward: asymmetric — limited premium at risk for multi-bagger revenue optionality if payers broaden access, but coverage resistance could keep upside muted.
• Speculative long IONS (Ionis) — 12–36 months, small allocation using long-dated calls. Rationale: binary exposure to Lp(a)-targeted therapeutics becoming commercially relevant; high upside if pivotal trials/readouts succeed and guidelines convert testing into treatment. Risk/reward: high-risk/high-reward — potential 3–5x on positive development vs total premium loss on trial/regulatory failure.